A Phase 1 interventional study of transcutaneous auricular vagus nerve stimulation in PARKINSON DISEASE (Disorder), sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Alabama at Birmingham · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Parkinson Disease by University of Alabama at Birmingham — 8 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · University of Alabama at Birmingham.
Among the 24 studies in Parkinson Disease by University of Alabama at Birmingham, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1, and was the 22nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →8 of the 24 studies in Parkinson Disease by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 30–80
University of Alabama at Birmingham · Sites in United States
Ages 18–99 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18–89
University of Alabama at Birmingham · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1
First in 2010; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 24 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 35 across the 20 interventional studies, 117 across the 4 observational. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
4 of the studies in Parkinson Disease by University of Alabama at Birmingham that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04735458University of Alabama at BirminghamInvestigating Inhibitory Control Networks in Parkinson's Disease | 2027-03-31 |
| NCT07557706University of Alabama at BirminghamUsing taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease | 2027-07-31 |
| NCT07661524University of Alabama at BirminghamPassive Versus Active Music Therapy Parkinson's Disease | 2027-10-01 |
| NCT07725315University of Alabama at BirminghamInvestigating the Increased Risk of Falls in Individuals With Parkinson's Disease Treated With Deep Brain Stimulation | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 24 studies in Parkinson Disease by University of Alabama at Birmingham, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active taVNS on Visit 2, Sham taVNS on Visit 3. Active taVNS is delivered at 30 Hz, 250 µs, 0.1-4 mA for 15 minutes. Sham taVNS is delivered at 0 mA output for 15 minutes. A minimum washout period of 48 hours will be observed between visits.
Device: transcutaneous auricular vagus nerve stimulation
Sham taVNS on Visit 2, Active taVNS on Visit 3. Active taVNS is delivered at 30 Hz, 250 µs, 1-4 mA for 15 minutes. Sham taVNS is delivered at 0 mA output for 15 minutes. A minimum washout period of 48 hours will be observed between visits
Device: transcutaneous auricular vagus nerve stimulation
Participants will sit quietly while receiving active nerve stimulation for 15 minutes. A gentle electrical current is delivered through hydrogel electrodes placed in the ear. The active stimulation parameters are set to 30 Hz, 250 µs, and 0.1-4 mA.
Change in heart rate
Assessment of how the body adjusts heart rate during taVNS and during physical challenges. Tests include the Valsalva maneuver (blowing into a mouthpiece for 15 seconds), deep breathing test (breathing deeply and evenly at a rate of 6 breaths/minute), lying-to-standing heart rate and blood pressure tests, and an isometric handgrip test (sustaining a handgrip contraction on a dynamometer at 30% maximal effort for 5 minutes). Heart rate is continuously monitored using a Polar HR monitor.
Time frame: During Visit 2 and Visit 3 (1-2 weeks after baseline, with 48 hour wash-out between visits 2 and 3), during and following 15 minutes of stimulation.
Change in blood pressure
Assessment of how the body adjusts blood pressure during taVNS and during physical challenges. Tests include the Valsalva maneuver (blowing into a mouthpiece for 15 seconds), deep breathing test (breathing deeply and evenly at a rate of 6 breaths/minute), lying-to-standing heart rate and blood pressure tests, and an isometric handgrip test (sustaining a handgrip contraction on a dynamometer at 30% maximal effort for 5 minutes). Blood pressure is measured manually using a sphygmomanometer.
Time frame: During Visit 2 and Visit 3 (1-2 weeks after baseline, with 48 hour wash-out between visits 2 and 3), during and following 15 minutes of stimulation.
Skin temperature
Infrared thermography will be used to assess facial, hand, and foot skin temperature.
Time frame: Before, during and immediately after both active and sham taVNS.
Autonomic Symptom Burden (COMPASS-31)
The Composite Autonomic Symptom Score 31 (COMPASS-31) is a validated, self-assessment questionnaire used to evaluate the severity and distribution of autonomic nervous system symptoms.Scores from each domain are weighted and summed to calculate a final Total Score. The Total Score ranges from 0 to 100. A higher score indicates a greater severity and wider distribution of autonomic symptoms (worse autonomic function), while a lower score indicates fewer and less severe autonomic symptoms (better autonomic function).
Time frame: Baseline (Visit 1)
Autonomic Symptom Severity (SCOPA-AUT)
The Scales for Outcomes in Parkinson's disease - Autonomic Dysfunction (SCOPA-AUT) is a self-administered questionnaire specifically developed to assess autonomic symptoms in individuals with Parkinson's disease. The questionnaire evaluates the frequency of problems experienced over the past month. Each item is scored on a 4-point Likert scale ranging from 0 ("never") to 3 ("often"). The Total Score is calculated by summing the responses of the 23 applicable items, with a possible range from 0 to 69. A higher score indicates a greater frequency and severity of autonomic dysfunction (worse autonomic functioning), while a lower score indicates fewer autonomic symptoms (better autonomic functioning).
Time frame: Baseline (Visit 1)
Physical Activity (Goodin Leisure-Time Exercise Questionnaire)
The Godin Leisure-Time Exercise Questionnaire (GLTEQ) is a brief, validated self-report instrument that assesses an individual's usual physical activity habits over a typical 7-day period. The questionnaire consists of 3 items asking participants to report the number of times per week they engage in physical activities lasting more than 15 minutes across three specific intensity levels. The Weekly Leisure-Time Activity Score is calculated by multiplying the reported weekly frequencies by their respective Metabolic Equivalent (MET) values and summing the results using the following formula: (9 x Strenuous) + (5 x Moderate) + (3 x Light). The minimum possible score is 0, and there is no theoretical maximum upper limit. A higher score indicates a greater volume and intensity of weekly physical activity (better physical activity level). Clinically, a score of 24 or higher is classified as "Active," 14 to 23 as "Moderately Active," and less than 14 as "Insufficiently Active/Sedentary".
Time frame: Baseline (Visit 1)
Physical Activity (International Physical Activity Questionnaire)
The International Physical Activity Questionnaire - Short Form (IPAQ-SF) is a validated self-report instrument used to estimate total physical activity and time spent sitting over the preceding 7 days. The questionnaire consists of 7 open-ended questions asking participants to recall the number of days per week and the amount of time usually spent per day engaged in specific intensities of physical activity lasting at least 10 minutes. Data are used to calculate the total physical activity expressed in Metabolic Equivalent of Task (MET)-minutes per week. The total MET-minutes/week is calculated by weighting the reported minutes per week for each activity category by a standard MET energy expenditure estimate (Walking = 3.3 METs, Moderate = 4.0 METs, Vigorous = 8.0 METs) and summing the values. The minimum possible score is 0, and there is no theoretical maximum upper limit. A higher MET-minutes/week score indicates a greater volume of physical activity.
Time frame: Baseline (Visit 1)
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.
Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 22 months is below that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Jul 2027 and completion Dec 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →